Clinical trial / 2008
Enteral probiotics did not reduce infection and increased mortality in severe acute pancreatitis.
In a double-blind trial, 296 patients with predicted severe acute pancreatitis received a multispecies probiotic preparation or placebo twice daily for 28 days. Infectious complications occurred in 30% of the probiotic group and 28% of the placebo group (relative risk 1.06, 95% CI 0.75-1.51). Mortality was higher with probiotics at 16% versus 6% for placebo (relative risk 2.53, 95% CI 1.22-5.25), alongside nine cases of bowel ischaemia.
- Study type
- Randomized controlled trial
- Who was studied
- 296 patients with predicted severe acute pancreatitis
- What was measured
- Infectious complications, mortality, and bowel ischaemia
THE PAPER
Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial.
Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG, Dutch Acute Pancreatitis Study Group. Lancet, 2008.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.